HOME >> BIOLOGY >> NEWS
ECCO 13 - Sunitinib prolongs survival in GIST patients after imatinib mesylate failure

Paris, France, Thursday 3 November 2005 - Updated results from a Phase III trial presented at the 13th European Cancer Conference (ECCO) show that sunitinib (SU11248) prolongs both progression-free and overall survival in patients with progressive metastatic and/or unresectable GIST whose disease has failed to respond to the standard therapy - imatinib mesylate.

This study was a double-blind, placebo-controlled, international, multicentre, Phase III trial involving 312 patients with GIST whose cancer had progressed despite previous treatment with imatinib mesylate. Failure of imatinib mesylate therapy was either the result of resistance or intolerance. Sunitinib treatment was in a repeated 6-week cycle consisting of a 50 mg capsule once daily for 4 weeks, followed by a 2-week break.

Results from the first planned interim analysis of this trial, disclosed at ECCO 13, demonstrate a 4-fold increase in the average time to progression (TTP) with sunitinib treatment, as compared to placebo. The estimated median TTP was 6.3 months with sunitinib, versus 1.5 months for placebo. Overall survival (OS) has also been estimated to be significantly greater with sunitinib therapy, although the average OS survival point has not yet been reached in either the sunitinib or placebo treatment arm.

Overall, treatment with sunitinib was well tolerated with fatigue, diarrhoea, nausea, sore mouth and skin discolouration proving to be the most common non-haematological side effects. Adverse events were generally mild to moderate and no severe effects (grade 4) were noted during the course of the study.

Dr George Demetri from the Dana-Farber Cancer Institute and Harvard Medical School, USA summarised: "These results from our global collaborative team provide important confirmatory evidence that documents the significant efficacy and acceptable tolerability of sunitinib (SU11248) in patients with metastatic GIST whose disease was resistant to imatinib, or th
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
3-Nov-2005


Page: 1 2 3

Related biology news :

1. Paclitaxel combined with bevacizumab prolongs progression free survival in metastatic breast cancer
2. Resveratrol prolongs lifespan and delays onset of aging-related traits in a short-lived vertebrate
3. New use for a cell toxin found to inhibit survival proteins in cancer cells
4. Glimmer of hope for Tahitian tree snails survival
5. Nexavar significantly extends overall survival by 44 percent in liver cancer patients
6. For many insects, winter survival is in the genes
7. HIV survival improves if patients stay in care
8. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
9. Pancreatic cancer markers identified, may predict survival
10. Salk scientists hammer out a pathway that promotes muscle cell survival in mice
11. Knocking out survival protein could aid leukemia treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... SAN FRANCISCO (PRWEB) , ... July 30, 2020 ... ... Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on ... diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes. As ...
(Date:7/10/2020)... ... , ... Today CJ BIO announced the first in a series of Food ... phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range ... 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual ...
(Date:7/1/2020)... ... 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit ... aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: John ... the organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions its ... MediVet Biologics since its formation in 2016, the company is relaunching itself under the ... on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has introduced ... configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter ... in a push-pull configuration; yielding fast fall time for a capacitive load. These ...
(Date:7/31/2020)... TORONTO (PRWEB) , ... July 29, 2020 , ... eSource ... and inefficiencies. This webinar will cover the history of eSource, the reasons it did ... From EMR/EHR to wearables, to site source, the industry is moving towards capturing data ...
(Date:7/22/2020)... ... 22, 2020 , ... Join experts from Reed Tech , Gary Saner, ... a one hour live webinar on Thursday, August 13, 2020 at 11am ... and medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical ...
Breaking Biology Technology:
Cached News: